- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT05224986
Lebensstilmuster und glykämische Kontrolle
The goal of the proposed study is to evaluate the feasibility and initial efficacy of stabilizing lifestyle behaviors to improve glucose control and body composition in patients with pre-diabetes.
The investigator proposes that following stable lifestyle behaviors will improve patients' glucose control, body composition, and liver fat. The results from this study has the potential to impact clinical practice and patient care.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Variability in lifestyle behaviors has been associated with adverse health, specifically poor glucose control. The project proposes to test whether reducing this variability improves glycemia in patients with pre-diabetes. If successful, this simple positive lifestyle message to keep stable behaviors has the potential to improve the health of millions of adults worldwide.
This project will enroll participants with pre-diabetes who have erratic lifestyle behaviors and randomize them to either maintain their usual habits (control group) or stabilize their behaviors (stability group). Both groups will be followed for 12 weeks. Before the start of the 12-week period, all participants will track their sleep for 2 weeks and will wear a glucose monitor to measure their glucose levels. At the start and end of the 12-week period, they will come to the research lab to undergo a glucose tolerance test. This test will measure how their body reacts to a glucose load. They will also undergo magnetic resonance imaging and spectroscopy scanning. This scan will provide information on body composition and liver fat content.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
New York
-
New York, New York, Vereinigte Staaten, 10032
- Columbia University Irving Medical Center
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Pre-diabetic kg/m2 (hemoglobin A1c 5.7-6.9%)
- 25 years or older
- BMI between 25-39.9 kg/m2
- Sleep duration ≥6 hours a night assessed with wrist actigraphy (for 14 nights)
- Variable bedtime, SD≥45 minutes.
Exclusion Criteria:
- Chronic Kidney Disease (GFR<60)
- Uncontrolled hypertension (≥160/100 mmHg)
- Obstructive Sleep Apnea
- Psychiatric or neurological disorder
- Prevalent cardiovascular disease
- Dyslipidemia (triglycerides≥200 mg/dL)
- Medications that affect insulin sensitivity, glucose concentrations, and body weight
- Non-day or rotating shift workers
- Travel across time zones
- Active participation in weight loss program or within past 3 months
- Current or past alcohol/drug abuse
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Unterstützende Pflege
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Single
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Kein Eingriff: Variable Schedule
Participants randomized to Variable Schedule (VS) will be asked to maintain their usual habits for 12 weeks. |
|
|
Experimental: Fixed Schedule
Participants randomized to Fixed Schedule (FS) will be asked to stabilize their lifestyle behaviors for 12 weeks. |
Participants will be asked to maintain a fixed schedule for 12 weeks. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Adipose Tissue Measurement - Total
Zeitfenster: 12 weeks
|
Measuring total adiposity. Measured by MRI, includes both subcutaneous and visceral adipose tissue. |
12 weeks
|
|
Adipose Tissue Measurement - Subcutaneous
Zeitfenster: 12 weeks
|
Measurement of subcutaneous adiposity using MRI. |
12 weeks
|
|
Adipose Tissue Measurement - Visceral
Zeitfenster: 12 weeks
|
Measurement of visceral adiposity using MRI. |
12 weeks
|
|
Glucose Area Under Curve
Zeitfenster: 12 weeks
|
Testing glycemic control.The primary outcome variable is glucose under the curve during the oral glucose tolerance test. |
12 weeks
|
|
Mean Amplitude of Glycemic Excursion and Standard Deviation of Mean Glucose
Zeitfenster: 12 weeks
|
Testing glucose variability. The primary outcome variables are mean amplitude of glucose excursion and standard deviation of average glucose. |
12 weeks
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Liver Fat Content
Zeitfenster: 12 weeks
|
This is to assess liver fat measured by MRS and MRI in %. |
12 weeks
|
|
Disposition Index
Zeitfenster: 12 weeks
|
This is to assess disposition index, measured using HOMA-IR. The disposition index is the product of the insulogenic index and homeostatic model of assessment for insulin resistance. |
12 weeks
|
|
Short-term Change in Glycemia
Zeitfenster: Baseline, up to 12 weeks
|
Assessing whether short-term glycemia is changed by measuring fructosamine using two-sample t-tests. |
Baseline, up to 12 weeks
|
|
Endothelial cell inflammation (sub-set, n≤10)
Zeitfenster: Baseline, 12 weeks
|
NF-κB nuclear fluorescence area for pilot study. |
Baseline, 12 weeks
|
|
White blood cells
Zeitfenster: Baseline, 12 weeks
|
Leukocytes and neutrophils |
Baseline, 12 weeks
|
|
Long-term Change in Glycemia
Zeitfenster: Baseline, 12 weeks
|
Assessing whether long-term glycemia is changed by measuring hemoglobin A1c using two-sample t-tests. |
Baseline, 12 weeks
|
|
Endothelial cell oxidative stress (sub-set, n≤10)
Zeitfenster: Baseline, 12 weeks
|
redox sensitive fluorogenic probe fluorescence intensity for pilot study. |
Baseline, 12 weeks
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Hauptermittler: Marie-Pierre St-Onge, Columbia University
- Hauptermittler: Blandine Laferrere, Columbia University
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- AAAT8914
- R01DK128154 (US NIH Stipendium/Vertrag)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .